Omeprazole–amoxicillin intermolecular complex

The Omeprazole–amoxicillin intermolecular complex refers to the physical and chemical interaction between the proton pump inhibitor (PPI) omeprazole and the beta-lactam antibiotic amoxicillin. This entity is not a biological target, such as a receptor or enzyme, but is instead a drug-drug association frequently utilized in the clinical eradication of Helicobacter pylori infections (StatPearls, 2023). Omeprazole acts by irreversibly inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells, thereby increasing gastric pH (PubMed, PMID: 11051354). This pH elevation is critical because amoxicillin, which targets bacterial penicillin-binding proteins to inhibit cell wall synthesis, is more stable and effective at higher pH levels (NIH, 2022). Research into the intermolecular complexation of these drugs focuses on how their chemical synergy improves the pharmacokinetic profile and bactericidal activity against H. pylori in the stomach (PubChem, 2024). The complexation may involve hydrogen bonding or other non-covalent interactions that influence the dissolution and absorption of the drugs. Consequently, this entity represents a pharmacological interaction used to optimize therapeutic outcomes rather than a site of drug action in the human body. It is often administered as part of a triple therapy regimen including a second antibiotic like clarithromycin.

Other names

Omeprazole-amoxicillin interactionAmoxicillin-omeprazole co-formulationPPI-antibiotic complex

Omeprazole inhibits the gastric H+/K+-ATPase (proton pump), while amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). The complexation facilitates increased amoxicillin stability via omeprazole-induced pH elevation.